Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD

By afschroeder • July 14, 2026

Goldberg SB, Ahn MJ, Baik C, De Castro Carpeño J, Cho BC, de Langen AJ, Fidler MJ, Goldman JW, Grønberg BH, Akamatsu H, Kim SW, Kim YJ, Le X, Marrone KA, Piotrowska Z, Riess JW, Shiraishi Y, Fraenkel PG, Merchan Ruiz B, Smith PE, Tang KH, Yu HA. Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD. Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-26-0704. Epub ahead of print. PMID: 42440354.

Tags: Hematology/Oncology, Publications

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

Waks AG, Segui E, Li T, Lipsyc-Sharf M, Kallfelz E, DiLullo M, Patel A, Rahman T, Junkins K, Rahee H, Frey AM, Kelly E, Stalteri[...]

Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape

Lipsyc-Sharf M, Hurvitz SA. Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape. J Clin Oncol. 2026 Jul 13:JCO2600672.[...]

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma

Tan CR, Gordan L, Richter J, DiLeo R, Mewawalla P, Larson S, Davies F, Oveisi D, Gupta-Werner N, Medhekar R, Yin X, Cortoos A, Armoon[...]